The aim of this study was to find cell lines with MLL PTD. RT-PCR indicated that 4/139 acute leukemia-derived cell lines carried this genetic alteration, all of them AML-derived. Cell line MUTZ-11 appears to be of special interest as this cell line not only carries an MLL PTD but also an FLT3 ITD (internal tandem duplication of fms-like tyrosine kinase).
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 
TO THE EDITOR
The glutathione S-transferase (GSTs) superfamily of enzymes catalyzes the conjugation of xenobiotics and potentially damaging oxidative metabolites with glutathione. Four major subfamilies of GSTs (a, m, p, y) can be distinguished in humans.
Several studies implicate GST polymorphisms in de novo cancer as well as cancers that are secondary to chemotherapy. In all cases, GST deficiency, rather than high GST activity, has been associated with an increased risk of cancer. However, because of its activity, GST has been associated with cancer-drug resistance, while GST deficiency of GSTT1 and GSTM1 could positively influence chemotherapeutic efficacy in some patients. 1 In the case of childhood acute lymphoblastic leukemia (ALL), conflicting results have been reported on the associations between GSTM1 and GSTT1 genotypes and outcome.
2,3 Stanulla et al. 4 recently showed a two-fold and 2.8-fold reduction in risk of relapse, respectively, relative to the presence of the GSTM1 or GSTT1. These findings encouraged the evaluation of the GST genotypes contribution to therapeutic outcome in larger, well-characterized ALL patient populations prospectively enrolled in the same protocol treatment. After informed consent, 356 patients were enrolled in the study here reported. Patients were treated within the AIEOP ALL 95 study. 5 The outcome of the 356 patients described here was similar to that of the 1360 patients enrolled in the whole AIEOP ALL 95 study [ and the median follow-up was 64 months. EFS curves were estimated according to Kaplan-Meier, with Greenwood standard error (s.e.), and compared with the log-rank test. The Cox model was used to adjust the effect of genotype status by known prognostic feature and was stratified by type of protocol (standard and medium vs high). The crude cumulative incidence of relapses was estimated, accounting for competing risk of death or resistance and the Gray test was used for comparison.
Genotype analyses were successfully performed in 338/353 (95.7%) for GSTT1 and GSTM1 and in 323/353 (91.4%) for GSTP1 genes; results were quite similar to those reported for the Caucasian population.
6 GSTT1 present: 84.6%, GSTT1 null: 15.4%, GSTM1 present: 53.2%, GSTM1 null 46.8%; GSTP1: Ile105/Ile105 and Ile105/Val 105 alleles: 90.5% and Val 105/Val105 allele : 9.5%. Figure 1 shows the EFS curves in patients according to different GST(s) genotypes. The analysis was restricted to 323 patients with full GST genotypes data. No significant difference in EFS was observed either by the univariate analyses or when the effect was adjusted by known prognostic factors in the Cox model. Since null genotype could increase the risk of toxicity death while decreasing the risk of relapse, the analysis of the risk of relapse was performed separately. The incidence curves represented in Figure 1 As mentioned before, conflicting data have been reported on the association between childhood ALL risk of relapse and GSTs polymorphisms. [2] [3] [4] In the two most recent studies reported in the literature and conducted in large number of childhood ALL, no particular associations with relapse were observed for the GSTT1 and GSTM1 genotypes 7, 8 and GSTP1. Figure 1 Probability of event-free survival and of relapse (upper and lower parts, respectively, of each diagram) for each of the GSTT1, GSTM1 and GSTP1 genotypes (from the top to the bottom) in 323 patients with known data for all three genotypes. Null/wild-type genotype: solid/ interrupted line: for GSTT1 and GSTM1, GSTP1 Val105/Val105 is indicated as GSTP1 (À/À) in solid line. GSTP1(+/+)(+/À), is referred to Ile105/ Ile105 and Ile105/Val105, respectively, and is indicated in interrupted line. polymorphisms within the investigated population was found to be in the expected range as reported in the literature, 3, 4 thus confirming that the sample was a reliable representation of the whole protocol study population. Unlike the results reported by Stanulla et al, 4 we did not find any correlation between the different GST(s) genotypes, prognostic factors and the relative risk of relapse. Treatment is not likely to play a role, being BFM and AIEOP ALL protocols very similar both in terms of treatment and overall results, at least since 1990. It should be emphasized that unlike the case-control methodology used in most of the studies reported so far, our study analyzed samples from a cohort of patients prospectively enrolled in a treatment protocol. This approach could reduce the limitations that hinder case-control studies.
It is likely that in the near future the possibility of investigating not only GST(s) genotypes but also polymorphisms occurring in several genes believed to play a role in drug detoxification, as offered by microarray technology, will help to elucidate individual patient risk profile, thus optimizing cancer chemotherapeutic regimens. Speranza'.We thank Dr Andrea Callegaro for the help in statistical analyses.
Alessandra Sala 
We read with interest the recent article in which Paquette et al 1 evaluated the in vitro and in vivo ability of interferon-a (IFN-a) to induce dendritic cell (DC) differentiation in chronic myeloid leukemia (CML). We agree with their conclusion that the therapeutic activity of IFN-a in CML may be because of its ability to stimulate the generation of DCs that can present CML-specific antigens.
We observed a lymphocytosis in bone marrow biopsy of three patients with CML in complete cytogenetic remission under IFN-a therapy, 2 years ago. 2 This prompted us to consider that IFN-a enhances the in vitro terminal differentiation of DCs and the recruitment of DCs of the immune system. 3 As B7-1 and B7-2 molecules, expressed by DCs, are essential for initiating antigenspecific T-cell responses, 4, 5 we evaluated their expression and the CD4/CD8 cell ratio in the peripheral blood of 15 patients with CML. These patients were treated following the guidelines criteria of the Italian Cooperative Study Group on CML. 6 In particular, 10 patients received IFN-a (9 million IU/daily) and five patients were treated with hydroxyurea (HU) at doses ranging between 1 and 2.5 g/daily.
Five out of 10 IFN-a-treated patients (group A) obtained a complete or major cytogenetic response within 9-18 months; this was maintained for a mean of 4.7 years (range 3-7). The other five patients treated with IFN-a (group B) for a mean of 1.6 years (range 1-2) or the five patients treated with HU (group C) for the same period of time, never achieved a cytogenetic response. Table 1 shows the results of the expression of surface marker molecules. Patients responsive to IFN-a showed a peculiar pattern of expression, with significant increase of B7-1 and B7-2 costimulatory molecules and CD8 lymphocytes. The percentage of expression of CD80 (1873.6) and CD86 (1472.7) molecules was significantly upregulated only in patients who achieved a complete or major cytogenetic response and treated by IFN-a in comparison with unresponsive patients also treated with IFN-a (CD80: 7.871.1, Po0.03; CD86: 2.870.5, Po0.008). Similarly, the percentage of CD8 lymphocytes (29.670.6) from IFN-a responsive patients was significantly increased in comparison with IFN-a (1873.2, Po0.01) or HU (1571.2, Po0.008) unresponsive patients. Figure 1 
